Research News
-
Summary of the 11th Annual Retinal Therapeutics Innovation Summit
Research NewsThe 11th annual Retinal Therapeutics Innovation Summit featured 25 presentations from industry professionals worldwide and more than 400 attendees.
-
Sepul Bio completes clinical trial enrollment for its USH2A retinitis pigmentosa treatment
Research NewsUltevursen from Sepul Bio progresses through phase 2b safety and efficacy clinical trial
-
FDA approves Lumvoa, a new treatment for thyroid eye disease
Research NewsApproval gives patients an additional option to manage TED symptoms
-
Belite Bio Submits New Drug Application to FDA for its Stargardt Treatment
Research NewsTinlarebant becomes first Stargardt treatment submitted to FDA for approval
-
Potential Oral Stargardt Treatment Advances to Phase 3 Clinical Trial
Research NewsPromising oral treatment moves closer for Stargardt patients.
-
Research News
2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research.
-
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201
-
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
